Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).

Trial Profile

Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP).

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs VGX 3400 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Mar 2015 Planned primary completion date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov record.
    • 16 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jul 2011 Pooled results from this and a parallel trial in the US have been presented at DNA Vaccines 2011, according to an Inovio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top